[ad_1]
The Competition Commission (CCI), India’s antitrust watchdog, on Monday approved the Platinum Owl acquisition Admission drug.
The proposed transaction involves the secondary acquisition of a 3% stake in the company by Platinum Owl Admission (based on outstanding shares).
Platinum Owl acts as trustee of the Platinum Jasmine A 2018 Trust, and the Abu Dhabi Investment Authority (ADIA) is the sole beneficiary and settlor of the Platinum Jasmine A 2018 Trust.
Intas is engaged in the development, manufacture and marketing of pharmaceutical formulations.
In separate portfolio, CCI approves acquisition of 100% equity and mandatory convertible bonds in five special purpose vehicles (SPVs) Infravit and allocation units Infravit CPHI-4 was used to partially finance the acquisition of SPV.
The five SPVs are located in Andhra Pradesh, Uttar Pradesh, Bihar and Maharashtra.
Transactions above a certain threshold require approval from regulators, who keep a close eye on unfair business practices in the market.
IndInfravit is a registered infrastructure investment trust and CPHI-4 (CPP Investment Board Private Holdings (4) Inc) is an investment holding company investing in a diversified portfolio of assets.
(This story has not been edited by Devdiscourse staff and was automatically generated from a syndicated feed.)
[ad_2]
Source link
